Potential role of BRCA2 in a mitotic checkpoint after phosphorylation by hBUBR1

Cancer Research

Volumn 60, Issue 6, 2000, Pages 1531-1535

  Futamura, Manabu ^a,b   Arakawa, Hirofumi ^a   Matsuda, Koichi ^a   Katagiri, Toyomasa ^a   Saji, Shigetoyo ^b   Miki, Yoshio ^c   Nakamura, Yusuke ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN;

ANIMAL CELL; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; GENETIC SUSCEPTIBILITY; MITOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; BRCA2 PROTEIN; CELL CYCLE PROTEINS; COS CELLS; GENE EXPRESSION REGULATION; GLUTATHIONE TRANSFERASE; IMMUNOHISTOCHEMISTRY; MITOSIS; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASES; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 0034653736     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Stratton, M. R., and Wooster, R. Hereditary predisposition to breast cancer. Curr. Opin. Genet. Dev., 6: 93-97, 1996.
2. Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., Bell, R., Rosenthal, J., Hussey, C., Tran, T., McClue, M., Frye, C., Hattier, T., Phelps, C., Haugen-Strano, A., Katcher, H., Yakumo, K., Gholami, Z., Shaffer, D., Stone, S., Bayer, S., Wray, C., Bogden, R., Dayananth, P., Ward, J., Tonin, P., Narod, S., Bristow, P. K., Norris, F. H., Helvering, L., Morrison, P., Rosteck, P., Lai, M., Barrett, J. C., Lewis, C., Neuhausen, S., Cannon-Albright, L., Goldgar, D., Wiseman, R., Kamb, A., and Skolnick, M. H. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (Washington DC), 266: 66-71, 1994.
3. Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., Micklem, G., Barfoot, R., Hamoudi, R., Patel, S., Rice, C., Biggs, P., Hashim, Y., Smith, A., Conner, F., Arason, A., Gudmundsson, J., Ficenec, D., Kelsell, D., Ford, D., Tonin, P., Bishop, T., Spurr, N. K., Ponder, B. A. J., Eeles, R., Peto, J., Devilee, P., Cornelisse, C., Lynch, H., Narod, S., Lenoir, G., Egilsson, V., Barkadottir, R. B., Easton, D. F., Bantley, D. R., Futreal, P. A., Ashworth, A., and Stratton, M. R. Identification of the breast cancer susceptibility gene BRCA2. Nature (Lond.), 378: 789-792, 1995.
4. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet, 349: 1505-1510, 1997.
5. Ford, D., Easton, D. F., Stratton M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Webr, B., Lenoir, G., Chang-Claude, J., Sobol, I. I., Teare, M. D., Struewing, J., Arason, A., Schereck, S., Peto, J., Rebbeck, T. R., Tonin, P., Neuhausen, S., Barkardottir, R., Eyfjord, J., Lynch, H., Ponder, B. A., and Gayther, S. A., and Zelada-Hedman, M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am. J. Hum. Genet., 62: 676-689, 1998.
6. Roa, B. B., Boyd, A. A., Volcik, K., and Richards, C. S. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat. Genet., 14: 185-187, 1996.
7. Fodor, F. H., Weston, A., Bleiweiss, I. J., McCurdy, L. D., Walsh, M. M., Tartter, P. I., Brower, S. T., and Eng. C. M. Frequency and cancer risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am. J. Hum. Genet., 63: 45-51, 1998.
8. Abeliovich, D., Kaduri, L., Lerer, I., Weinberg, N., Amir, G., Sagi, M., Zlotogora, J., Heching, N., and Peretz, T. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 3% of early-onset breast cancer patients among Ashkenazi women. Am. J. Hum. Genet., 60: 505-514, 1997.
9. Tavtigian, S. V., Simard, J., Rommens, J., Couch, F., Shattuck-Eidens, D., Neuhausen, S., Merajver, S., Thorlacius, S., Offit, K., Stoppa-Lyonnet, D., Belanger, C., Bell, R., Berry, S., Bogden, R., Chen, Q., Davis, T., Dumont, M., Frye, C., Hattier, T., Jammulapati, S., Janecki, T., Jiang, P., Kehrer, R., Leblanc, J. F., and Goldgar, D. E. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat. Genet., 12: 333-337, 1996.
10. Sharan, S. K., Morimatsu, M., Albrecht, U., Lim, D. S., Regel, E., Dinh, C., Sands, A., Eichele, G., Hasty, P., and Bradley, A. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature (Lond.), 24: 804-810, 1997.
11. Mizuta, R., LaSalle, J. M., Cheng, H. L., Shinohara, A., Ogawa, H., Copeland, N., Jenkins, N. A., Lalande, M., and Alt, F. W. RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein. Proc Natl. Acad. Sci. USA, 94: 6927-6932, 1997.
12. Patel, K. J., Vu, V. P., Lee, H., Corcoran, A. F. C., Evans, M. J., Colledge, W. H., Friedman, L. S., Ponder, B. A., and Venkitaraman, A. R. Involvement of Brca2 in DNA repair. Mol. Cell, 1: 347-357, 1998.
13. Paulovich, A. G., Toczyski, D. P., and Hartwell, L. H. When checkpoints fail. Cell. 88: 315-321, 1997.
14. Roberts, B. T., Farr, K. A., and Hoyt, M. A. The Saccharomyces cerevisiae checkpoint gene BUB1 encodes a novel protein kinase. Mol. Cell. Biol., 14: 8282-8291, 1994.
15. Taylor, S. S., and McKeon, F. Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage. Cell, 89: 727-735, 1997.
16. Cahill, D. P., Lengauer, C., Yu, J., Riggins, G. J., Willson, J. K., Markowitz, S. D., Kinzler, K. W., and Vogelstein, B. Mutations of mitotic checkpoint genes in human cancers. Nature (Lond.) 312-300-303, 1998.
17. Durfee, T., Becherer, K., Chen, P. L., Yen, S. H., Yang, Y., Kilburn, A. E., Lee, W. H., and Elledge, S. J. The retinoblastoma protein associates with the protein phosphatase type 1 catalytic subunit. Genes Dev., 7: 555-569, 1993.
18. Altsehul, S. F., Gish, W., Miller, W., Myers, E. W., and Lipman, D. J. Basic local alignment search tool. J. Mol. Biol., 215: 403-410, 1990.
19. Pearson, W. R., and Lipman, D. J. Improved tools for biological sequence comparison. Proc. Natl. Acad Sci. USA., 85: 2444-2448, 1988.
20. Taylor, S. S., Ha, E., and McKeon, F. The human homologue of Bub3 is required for kinetochore localization of Bub1 and a Mad3/Bub1-related protein kinase. J. Cell. Biol., 142: 1-11, 1998.
21. Hartwell, L. Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell, 71: 543-546, 1992.
22. Chan, G. K. T., Schaar, B. T., and Yen, T. J., Characterization of kinetochore binding domain of CENP-E reveals interactions with the kinetochore proteins CENP-F and BUBR1. J. Cell. Biol., 143: 49-63, 1998.
23. Jablonski, S. A., Chan, G. K., Cooke, C. A., Earnshaw, W. C., and Yen, T. J. The hBUB1 and hBUBR1 kinases sequentially assemble onto kinetochores during prophase with hBUBR1 concentrating at the kinetochore plates in mitosis. Chromosoma (Berl.), 107: 386-396, 1998.
24. Chen, J., Silver, D. P., Walpita, D., Cantor, S. B., Gazdar, A. F., Tomlinson, G., Couch, F. J., Weber, B. L., Ashley, T., Livingston, D. M., and Scully, R. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol. Cell. 2: 317-328, 1998.
25. Vaughn, J. P., Cirisano, F. D., Huper, G., Berchuck, A., Futreal, P. A., Marks, J. R., and Iglehart, J. D. Cell cycle control of BRCA2. Cancer Res., 56: 4590-4594, 1996.
26. Bertwistle, D., Swift, S., Marston, N. J., Jackson, L. E., Crossland, S., Crompton, M., R., Marshall, C. J., and Ashworth, A Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res., 57, 5485-5488, 1997.